SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients Read more about SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain Read more about Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain
Evaluation of Autogenous Demineralized Dentin Graft Vs Autogenous Bone Graft in Management of Intrabony Defects Read more about Evaluation of Autogenous Demineralized Dentin Graft Vs Autogenous Bone Graft in Management of Intrabony Defects
Patients´ Mental and Physical Health After Covid-19 Treated in ICU in Sweden Read more about Patients´ Mental and Physical Health After Covid-19 Treated in ICU in Sweden
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2) Read more about Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC Read more about Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Stellate Ganglion Block with Lidocaine for the Treatment of COVID-19-Induced Parosmia Read more about Stellate Ganglion Block with Lidocaine for the Treatment of COVID-19-Induced Parosmia
MIST Versus M-MIST for the Treatment of Intrabony Defects Read more about MIST Versus M-MIST for the Treatment of Intrabony Defects
Nutritional Intervention and Rehabilitation Treatment in Patients With Post-COVID Condition Read more about Nutritional Intervention and Rehabilitation Treatment in Patients With Post-COVID Condition
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma Read more about A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
